Biogen (BIIB) drug Aduhelm (Aducanumab) Approved by FDA for Alzheimer’s Disease Treatment – #stocks chatter


Biogen (BIIB) drug Aduhelm (Aducanumab) Approved by FDA for Alzheimer's Disease Treatment
Biogen's Aduhelm has been approved by the FDA to treat Alzheimer's Disease. Trading of Biogen (BIIB) is still halted as of 11:23 AM (Eastern).

Aduhelm targets amyloid plaque deposits, long thought to be associated with the cognitive decline of Alzheimer's Disease. There are still many hurdles with translating the drug to profits, as a followup study is pending. Pricing concerns based on drug efficacy raised by the Institute for Clinical and Economic Review (ICER) may also lower the upper limit of profitability. Insurers may be hesitant to cover Aduhelm without a clearer demonstration of efficacy.



Please enter your comment!
Please enter your name here

1 + eighteen =

Leave the field below empty!

This site uses Akismet to reduce spam. Learn how your comment data is processed.